Abbott India

1944
 
 - All shares issued to Boots Pure Drug Co., Ltd.  Only 5 shares
 issued
 for cash.
 
 1963
 
 - 2,00,000 shares issued to the present Company.
 
 1965
 
 - The Company was incorporated on 15th December.  The Company
 Manufacture `Boots' brand of medical and pharmaceutical products and
 agricultural and animal health products.  The leading lines of
 manufacture includes insulin injections, anti-dysentery drugs,
 vitamin
 preparations, penicillin preparations, sulphonamide tablets,
 household
 remedies, animal health products of Mindif series and
 agro-chemicals.
 
 - The plant with a licensed capacity of 1,500 mega units per annum
 was
 commissioned in January.  In September, a sterile manufacturing unit
 for the vialling of insulin injections was commissioned.
 
 - On 19th October, the Company entered into a technical
 collaboration
 agreement with Boots Pure Drug Co. Ltd., England for manufacturing
 crystalline insulin and formulations thereof and agreed to pay to
 them
 at the rate of 3% on the sale value of basic crystalline insulin
 used
 in the manufacture of preparations thereof, subject to a maximum of
 5,000 per annum.
 
 - In December, 2,00,000 shares issued to public (prem. Rs 13 per
 shares).
 
 1969
 
 - 25,000 shares issued at par to L.I.C., U.T.I. and I.C.I.C.I. on
 conversion of 5% debenture holdings.
 
 1971
 
 - The name of the Company was changed from Boots Pure Drug Co. 
 (India)
 Ltd., to the present one from 1st November.  The name was further
 changed to Boots Pharmaceuticals Ltd., from 1st January.
 
 1973
 
 - 25,000 shares issued at par to L.I.C., U.T.I. and I.C.I.C.I. on
 conversion of 5% debenture holdings.
 
 1976
 
 - The Company undertook to set up a new chemical plant at Ahmednagar,
 a
 backward area in Maharashtra, for the manufacture of Ibuprofen from
 the
 basic stage in technical collaboration with its parent company.
 Ibuprofen is a raw material of Boots original research.
 
 - 7,75,000 Bonus shares issued in the proportion 1:1.
 
 1977
 
 - 1,48,150 Right Equity shares issued to Indian shareholders (prem. 
 Rs
 3.50 per shares: prop. 2:9)
 
 1979
 
 - 2,66,050 Bonus shares issued in prop. 1:3.
 
 1983
 
 - The Company issued 1,70,000-15% non-convertible debentures of Rs
 100
 each.  These debentures were redeemed on 5th October, 1990 at a
 premium
 of Rs 5 per debenture.
 
 - Boots Company PLC, England voluntarily decided to dilute its
 shareholding in the Company by disinvesting 3,00,000 equity share of
 Rs
 10 each at a premium of Rs 45 per share.
 
 - The Company also issued 4,27,290 No. of Equity shares of Rs 10
 each
 at a premium of Rs 45 per share as rights to resident Indian equity
 shareholders.
 
 - Out of the total issue of 7,27,280 No. of equity share, 6,81,088
 shares were offered as rights to shareholders other than Boots
 Company
 PLC, England in the proportion 2:5.  Only 6,12,031 shares were taken
 up.  Out of the remaining 46,192 shares, 36,364 shares were offered
 to
 employees Including Indian working directors)/workers on equitable
 basis and 9,828 shares were offered to business associates of the
 Company.  The unsubscribed portion of 69,057 shares of the
 shareholder's quota were allotted to employees/workers of the
 Company.
 
 - The object of rights issue and offer for sale was to reduce the
 holding of Boots Company PLC, England in the Company from 53% to
 40%.
 
 1984
 
 - 13,58,520 Bonus equity shares issued in prop. 3:5.
 
 1986
 
 - Applications were made to Government for expansion of capacity
 upto
 200 tonnes per annum for Ibuprofen and an endorsement of capacity
 upto
 300 M.U. for highly purified insulin.
 
 - 4,27,280 new equity shares were offered as Rights to the resident
 Indian equity shareholders at a premium of Rs 45 per shares.
 
 1987
 
 - The Company received a letter of intent for both the products and
 the
 expansion capacity of Ibuprofen was being implemented.
 
 - An application was made for an industrial license to produce a
 bulk
 drug, Ranitidine Hydrochloride and its formulations.
 
 - 40,50,000 bonus equity shares issued in prop. 1:1.
 
 1988
 
 - `Advene' a new anti-peptic ulcerant and `Froben' a more potent
 anti-rheumatic drug were launched.
 
 - The Company undertook a project to set up a new formulation
 factory
 at Jejuri in Pune district.
 
 1989
 
 - A number of new products, namely Brufen Junior Syrup, Chota
 Strepsils
 Icy, Optrex Eye Lotion, Highly Purified Insulins and Nausidome were
 launched during the year.
 
 1991
 
 - A few new products like Human Insulin's, Frozen SR. and Optren Eye
 Drops were launched during the year.
 
 1994
 
 - Products such as Novopen, Human mixtard, Mixtard penfills were
 launched.
 
 - Beem Healthcare Ltd., Lenbrook Pharmaceuticals Ltd. and Valencia
 Pharmaceuticals Ltd are the subsidiaries of the Company.
 
 1995
 
 - It is proposed to change the name of the company to Knoll
 Pharceuticals Ltd. effective 31st October, name was changed to Knoll
 Pharmaceuticals Ltd.
 
 1997
 
 - Clivarine, an anticoagulant low molecular weight heparin
 preparation
 used for the prophylasix of deep vein thrombosis was launched.
 
 - The Company has acquired the product Epilex for a total
 consideration
 of Rs 9.90 crores.  The product is used in the treatment of
 epilepsy.
 
 - The new Goa plant of Knoll Pharmaceuticals, a part of the BASF
 group,
 has been set up.  BASF India has also set up two state-of-the-art
 plants to manufacture speciality dyes and dispersons in Mangalore
 and
 these were commissioned.
 
 - Knoll Pharma is currently the fifth-largest domestic formulations
 company.  It is likely to use the proceeds to acquire formulation
 brands in the cardiovascular, antibiotic and neurology segments.
 
 - Lupharma GmbH, a wholly owned subsidiary of Knoll AG of Germany,
 is
 making a public offer for the acquisition of a further 11 per cent
 holding in Knoll Pharmaceuticals Ltd (KPL), the Indian arm of the
 business.
 
 - Knoll India has recently entered into a co-marketing arrangement
 with
 SmithKline Beecham Pharmaceuticals (India) for the latter's
 formulation
 of amoxycillin and clavulanic acid.
 
 - Knoll India is to launch new products from the research pipelines
 of
 both Knoll AG and the erstwhile Boots plc.
 
 1998
 
 - KPL launched an anticoagulant low molecular weight heparin
 preparation - Cremaffin - used for the prophylaxis of deep vein
 thrombosis.
 
 - Lupharma GmbH, a wholly-owned subsidiary of Knoll AG of Germany,
 had
 made a public offer for acquisition of a further 11 per cent holding
 in
 Knoll Pharmaceuticals in order to take its stake up to 51 per cent
 from
 the current levels of 40 per cent.
 
 1999
 
 - Beem Healthcare which was engaged in marketing of consumer brands
 has
 been merged with Knoll with effect with July 1998.
 
 - Knoll Pharma has entered into a three-way pact with the
 Gujarat-based
 Torrent Pharmaceuticals and Danish giant, Novo Nordisk, in the
 anti-diabetes (human insulin) segment.
 
 2000
 
 - The Company has entered into a agreement with Kalpataru Homes for
 the
 assignment of the leasehold.
 
 - Ranbaxy Laboratories Ltd (RLL) has entered into an agreement with
 Knoll Pharmaceuticals Ltd (KPL) to market the latter's leading
 brands
 in select overseas markets.
 
 2001
 
 - Lupharma UK Holding One Ltd., a wholly-owned subsidiary of
 Lupharma
 GmbH has proposed to acquire 82,62,000 shares i.e. 51 per cent of
 the
 share capital of Knoll Pharmaceuticals from Lupharma Gmbh.
 
 2002
 
 -Knoll Pharmaceuticals, the maker of popular painkiller Brufen, has
 changed its name to Abbott India following global takeover of Knoll's
 majority stakeholder - German firm BASF Pharma - by US drug major
 Abbott Laboratories.
 
 2003
 
 -Mr V D Narkar, Director of Abbott India Ltd, has resigned with
 effect from June 19, 2003.
 
 -Mr.Ashok Dayal is appointed as Additional Director of the company.
 
 -Scheme of amalgamation of Lenbrook Pharmaceuticals (a wholly owned
 subsidiary of the company) with the company.
 
 2008
 
 - Abbott India Ltd has informed that the Board of Directors of the
 Company at its meeting held on February 14, 2008, has appointed Mr.
 Thomas Dee as the Additional Director of the Company.
 
 2009
 
 -Abbott India Ltd has recommended a dividend of Rs 14.00/- per share
 
 
 2010
 
 -Abbott India Ltd has recommended a dividend of Rs 17.00/- per share
 
 
 2011
 
 -Abbott India Ltd has recommended a dividend of Rs 17.00/- per share
 
 
 2012
 
 -Abbott India Ltd has recommended a dividend of Rs 17.00/- per share
 
 
 2013
 -Abbott has been named the �Multinational Pharmaceutical Company of
 the Year� for the third consecutive year at the 2013 Frost & Sullivan
 India Healthcare Excellence Awards held in Mumbai.
 -Abbott India announced the national results from astudy assessing
 the prevalence of hypothyroidism in India that was published in the
 July 2013 issue of the Indian Journal of Endocrinology and
 Metabolism. 
 
 2014
 -Abbott, one of the largest diversified global healthcare companies
 and the number one pharmaceutical company in India, in partnership
 with the Indian Thyroid Society (ITS), announced the launch of a
 thyroid awareness initiative in Uttar Pradesh and Uttarakhand. 
 - Abbott was awarded the prestigious Golden Peacock Innovation
 Management Award at the
 8th International Conference on Corporate Social Responsibility held
 in Bangalore.